Company
Aspire Health
Aspire Health publishes compounded semaglutide, compounded tirzepatide, oral semaglutide, brand semaglutide and brand tirzepatide, from $129 to $299 a month.
- 5 programs
- 5 molecules
- 10 readings
Read from aspirehealth.care on September 3, 2026. This page records what the company publishes. It is not a review and takes no position on the company.
Go to Aspire Health
We earn nothing from this link. Aspire Health has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
What it costs
first month, everything required included · ◯ $129 advertised · 0.25 mg weekly dose, 10-week supply, 1 vial
first month, everything required included · ◯ $149 advertised · 2.5 mg weekly dose, 4-week supply, 1 vial
first month, everything required included · ◯ $149 advertised · Oral Wegovy 1.5 mg/4 mg
first month, everything required included · ◯ $199 advertised · Wegovy 0.25 mg/0.5 mg, 4 weeks (listed price; insurance may lower it)
first month, everything required included · ◯ $299 advertised · Zepbound 2.5 mg, 4 weeks (listed price; insurance may lower it)
Terms
| Membership | Required, $75 per month. The LoseIt Program is $75 monthly and provides ongoing medical oversight, follow-up visits, secure messaging, and care coordination to support your treatment safely and consistently. The program is billed monthly. Medication costs are billed separately and are based on your prescribed treatment plan. When compounded medication is prescribed, it is offered in 1-, 3-, or 6-month packages, billed upfront. Active enrollment in the LoseIt Program is required to continue medication therapy. |
|---|---|
| Consultation fee | Charged, and the amount is not published. Consultation fees compensate providers for reserved time, clinical review, administrative preparation, and related services. Consultation fees are generally non-refundable once a consultation, clinical review, asynchronous evaluation, or other provider service has occurred. |
Not yet checked: pharmacy and states.
Terms can differ between this company’s programs; each entry carries its own.
Programs
| Entry | Provider | Form | Per month at its shortest term | Link |
|---|---|---|---|---|
| TR-0403 | Aspire Health | Injection, vial | $129 0.25 mg weekly dose, 10-week supply, 1 vial | Record |
| TR-0404 | Aspire Health | Injection, vial | $149 2.5 mg weekly dose, 4-week supply, 1 vial | Record |
| TR-0407 | Aspire Health | Oral tablet | $149 Oral Wegovy 1.5 mg/4 mg | Record |
| TR-0405 | Aspire Health | $199 Wegovy 0.25 mg/0.5 mg, 4 weeks (listed price; insurance may lower it) | Record | |
| TR-0406 | Aspire Health | $299 Zepbound 2.5 mg, 4 weeks (listed price; insurance may lower it) | Record |
Notes
Recorded against this company rather than one program.
September 2, 2026
- 1. Aspire Health states two different, unreconciled monthly non-medication fees: the semaglutide and tirzepatide product pages each say 'Monthly Medical Care: $49 — Includes provider visits, messaging, prescription management, and ongoing medical support. Medication priced separately (see tables above)', while the FAQ separately describes a 'LoseIt Program' at $75/month whose active enrollment 'is required to continue medication therapy.' Neither page mentions or reconciles the other figure. The membership entry above uses the $75 LoseIt Program figure since it is the one explicitly tied to required enrollment; the $49 'Monthly Medical Care' quote ('Monthly Medical Care: $49') from https://aspirehealth.care/tirzepatide-for-weight-loss/ and https://aspirehealth.care/semaglutide-for-medical-weight-management/ is flagged here rather than recorded a second time. Separately, https://aspirehealth.care/service-areas/ lists 49 state names (every state except Alabama) grouped as 'Western/Central/Eastern States,' but the page explains these are color-coded on an interactive map as 'Currently Licensed' vs. 'Coming Soon' — this text-extraction tool cannot read the map's color-coding, so which of the 49 are actually served today could not be confirmed; states.list is left empty rather than asserting all 49 as current coverage. The Wegovy/Zepbound dose tables are captioned 'Pricing varies based on insurance coverage. Patients should verify benefits directly with their insurance provider,' so it is unclear whether the listed dollar figures are a cash-pay price or already insurance-adjusted; recorded as-is with that caveat rather than labeled 'cash price'.
Before you act
Cite this
Treatment Registry. (2026). Aspire Health: recorded programs and prices. Last verified September 3, 2026. Retrieved [your access date], from https://treatmentregistry.com/providers/aspire-health